The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Vaccines to Prevent Infections by Oncoviruses
Open accessAbstract
It has been estimated that viruses are etiological agents in approximately 12% of human cancers. Most of these cancers can be attributed to infections by human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and Kaposi's sarcoma–associated herpesvirus (KSHV). Prophylactic vaccines against other pathogenic viruses have an excellent record as public health interventions in terms of safety, effectiveness, and ability to reach economically disadvantaged populations. These considerations should prompt efforts to develop and implement vaccines against oncoviruses. Safe and effective HBV and HPV vaccines, based on virus-like particles, are commercially available, and the major focus is now on vaccine delivery, especially to low-resource settings. HCV and EBV vaccines are under active development, but few clinical trials have been conducted, and none of the candidate vaccines has proven to be sufficiently effective to warrant commercialization. Efforts to develop KSHV vaccines have been more limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cancer-prevention vaccines, such as those for human papillomavirus and HBV, have greatly reduced the incidence or certain virally driven cancers, including HBV-related HCC130.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [130]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577
RetractedIdentification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,608
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · cited 1×
“Human T cell leukemia virus type 1 (HTLV1) was first identified in 1980 from a patient with cutaneous T cell leukemia (66).”
BackgroundThe causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A. T., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,587
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C., Hwang, L., & Chien, C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,856
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA
Epstein, M. A., Achong, B. G., & Barr, Y. M. (1964) · The Lancet · doi:10.1016/s0140-6736(64)91524-7 · Cited by 2,793
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
Research works printed but not linked: 7
- Hino S, 1997, Leukemia, 11, 57
- 37. Howley PM, Lowy DR. 2007. Pappillomaviruses. See Ref. 48, pp. 2299–354
- Knipe DM, 2007, Field's Virology
- 51. Latirmore MD, Franchini G. 2007. Human T-cell leukemia types 1 and 2. See Ref. 48, pp. 2071–105
- Mast EE, 2004, Vaccines, 205
- 68. Richardson AB, Kieff E. 2007. Epstein-Barr virus. See Ref. 48, pp. 2655–700
- Westmoreland SV, 2008, Comp. Med., 58, 31
Cited by
Sorted by citations
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
Human Viral Oncogenesis: A Cancer Hallmarks Analysis
Mesri, E. A., Feitelson, M. A., & Münger, K. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.011 · Cited by 672
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
Pandya, P. H., Murray, M. E., Pollok, K. E., & Renbarger, J. L. (2016) · Journal of Immunology Research · doi:10.1155/2016/4273943 · Cited by 270
Metadata
- Authors
- Schiller, J. T., & Lowy, D. R.
- Affiliations
- National Cancer Institute (US)
- Venue
- Annual Review of Microbiology
- Publisher
- Annual Reviews
- Published
- 2010-10-13
- Volume
- 64
- Issue
- 1
- Pages
- 23-41
- ISSN
- 0066-4227 (ISSN-L)
- 1545-3251
- PMC
- PMC6264788
- OpenAlex
- W2118603752
- Cited by
- 101
- References
- 85
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 11 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 9 · 2015: 2 · 2014: 4 · 2013: 9 · 2012: 15
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Annual Review of Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIABC010579)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- viral etiology of cancer, human papillomavirus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, virus-like particle vaccine, vaccine delivery, resource-limited settings, vaccine safety and effectiveness
- MeSH terms
- Herpesvirus 4, Human, Hepatitis B, Hepatitis B virus, Hepatitis C, Herpesviridae Infections, Humans, Neoplasms, Retroviridae, Viral Vaccines, Hepacivirus, Herpesvirus 8, Human, Epstein-Barr Virus Infections, Papillomaviridae, Papillomavirus Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
